Abstracts

BRAIN PET IMAGING OF MICROGLIA IN MACAQUES WITH SIV ENCEPHALITIS

Microglial activation (neuroinflammation) is hypothesized to play a central role in neuronal damage associated with HIV. In this study we wanted to image the translocator protein (TSPO), a mitochondrial membrane receptor overexpressed in activated microglia in macaques infected with a neuro-tropic SIV strain (SIVsm804E), before and after inoculation, using [18F]-DPA714 PET. Dynamic PET imaging with…

ART-TREATED PATIENT PLATELETS SHELTER INFECTIOUS HIV PREDICTING LOW CD4+T-CELL COUNTS

Beside hemostasis, human platelets exert several immune functions and interact with infectious pathogens including HIV that platelet internalize in vitro. Yet, in vivo evidence for HIV-containing platelets and their role in AIDS remain elusive. Immunological non-responder patient (InR) represents 20% of overall cART treated patients for which no clear treatment is available so far. In…

PHASE I CLINICAL TRIAL OF AN MRNA-BASED THERAPEUTIC VACCINE AGAINST HIV-1 INFECTION

The efficacy of therapeutic vaccines has been modest. The combination of new vectors targeting dendritic cells (DC) pathways and new antigenic sequences to redirect responses toward target unmutated epitopes could be necessary to achieve the remission of HIV-1 infection. We performed the first-in-human clinical trial with naked mRNA (iHIVARNA) encoding DC activation signals (TriMix:CD40L+CD70+caTLRA4) combined…

HIV ANTIBODY GLYCOFORMS MODULATE IMMUNE COMPLEX-DRIVEN INNATE AND ADAPTIVE IMMUNITY

HIV broadly neutralizing antibodies (bNAbs) confer protection following passive immunization, but the immunological mechanisms that drive their development in a fraction of HIV infected individuals are poorly understood. Structural features of bNAbs indicate that they originate from extensive B cell germinal center reactions, which rely on immune complex (IC)-mediated delivery of antigen to follicular dendritic…

EFFECT OF SWITCHING TO RALTEGRAVIR AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION

Inflammation and immune activation markers associated with end-organ diseases like atherosclerosis are higher in treatment-suppressed HIV patients than in non-HIV population. No therapies have been developed to effectively target these mediators. A decrease of immune activation markers after raltegravir intensification and anti-inflammatory properties of the angiotensin receptor antagonist losartan have been reported. The objective of…

A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY

HIV infection is associated with persistent upregulation of PD-1, LAG-3, TIGIT and perhaps other checkpoint molecules, particularly on HIV-specific T cells. We hypothesize that simultaneous engagement of multiple targets via bispecific antibodies (BsAbs) will enhance anti-HIV efficacy compared to single or combination approaches. Two BsAbs targeting the negative checkpoint receptors PD-1 & LAG-3 and PD-1…